SCHEDULE: Janus Henderson Discloses Tarsus Pharmaceuticals Stake

Janus Henderson Group plc has reported a beneficial ownership of 5.3% in Tarsus Pharmaceuticals, Inc., holding 2,240,963 shares as of March 31, 2026.

Summary

• Janus Henderson Group plc, through its various asset management subsidiaries, has filed a Schedule 13G indicating beneficial ownership of 2,240,963 shares of Tarsus Pharmaceuticals, Inc. common stock.
• This holding represents 5.3% of the class of securities.
• The filing specifies that the shares are held across multiple managed portfolios, with investment and/or voting discretion exercised by the asset managers.
• Janus Henderson Group plc disclaims ownership of dividends and proceeds from the sale of these securities, as these rights belong to the Managed Portfolios.
• No single managed portfolio owns more than five percent of Tarsus Pharmaceuticals, Inc. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it indicates institutional interest but provides no operational or financial performance data for Tarsus Pharmaceuticals, Inc.

Positives

• Significant institutional ownership by Janus Henderson Group plc, indicating confidence in Tarsus Pharmaceuticals.
• The filing clearly delineates ownership and control, providing transparency to the market.

Negatives

• The filing does not contain financial performance data or operational updates for Tarsus Pharmaceuticals, Inc., making it difficult to assess the company's current health.
• Janus Henderson Group plc disclaims beneficial ownership of dividends and sale proceeds, suggesting a passive investment role rather than active strategic involvement.

Risks

• The primary risk is the potential for Janus Henderson Group plc to divest its stake, which could negatively impact Tarsus Pharmaceuticals' stock price due to reduced institutional support.
• As a Schedule 13G filing, it indicates passive investment, meaning Janus Henderson is not actively seeking to influence or control the company's management or policies, which could leave Tarsus Pharmaceuticals without a significant strategic partner among its large shareholders.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Tarsus Pharmaceuticals, Inc.'s future performance.

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G from established asset managers such as Janus Henderson Group plc often signal a level of confidence in the target company's long-term prospects, though the passive nature of a 13G filing suggests it's not an activist stake.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception.
• Management of Tarsus Pharmaceuticals: The presence of a large institutional holder like Janus Henderson may be viewed positively, though the passive nature of the holding limits direct influence on strategic decisions.

Next Steps

• Janus Henderson Group plc will continue to monitor its investment in Tarsus Pharmaceuticals, Inc.
• Further filings may be required if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Janus Henderson Group plc, Tarsus Pharmaceuticals, Inc., Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management